Tricyclics and malignant syndrome.

Area of Science:

• Clinical Pharmacology
• Neuroscience
• Psychiatry

Background:

• Neuroleptic Malignant Syndrome (NMS) is a severe reaction typically associated with antipsychotic medications.
• Tricyclic antidepressants (TCAs) are commonly used for depression but can have diverse side effect profiles.

Purpose of the Study:

• To report an uncommon adverse event potentially mimicking NMS.
• To investigate the role of trimipramine in the development of NMS-like symptoms.

Main Methods:

• Case report of a depressed patient.
• Clinical observation of adverse drug reaction.
• Analysis of drug properties and potential mechanisms.

Main Results:

• A patient treated with trimipramine developed a syndrome clinically and biologically similar to NMS.
• No concurrent use of neuroleptic medications was noted.
• The antidopaminergic activity of trimipramine is proposed as the causative factor.

Conclusions:

• Trimipramine, a TCA, can induce NMS-like symptoms independently of neuroleptic use.
• The antidopaminergic effects of TCAs should be considered in differential diagnosis of NMS.
• This case highlights a rare but serious potential side effect of trimipramine therapy.